Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04645953
Recruitment Status : Recruiting
First Posted : November 27, 2020
Last Update Posted : September 16, 2021
Sponsor:
Information provided by (Responsible Party):
Alexza Pharmaceuticals, Inc.

Brief Summary:
This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.

Condition or disease Intervention/treatment Phase
Cyclic Vomiting Syndrome Combination Product: 3mg AZ-010 Combination Product: 1mg AZ010 Combination Product: Staccato Placebo Phase 2

Detailed Description:
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Double Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome
Actual Study Start Date : February 11, 2021
Estimated Primary Completion Date : December 15, 2021
Estimated Study Completion Date : January 15, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1mg AZ010
Single orally-inhaled dose
Combination Product: 1mg AZ010
Subject will receive a single inhaled dose (1mg)

Experimental: 3mg AZ010
Single orally-inhaled dose
Combination Product: 3mg AZ-010
Subject will receive a single inhaled dose (3mg)

Experimental: Placebo
Single orally-inhaled dose
Combination Product: Staccato Placebo
Subject will receive a single inhaled dose (Staccato Placebo)




Primary Outcome Measures :
  1. The number of vomiting/retching events in the 2 hours following treatment. [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. Number of adverse events as a measure of safety [ Time Frame: 24 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adult males and females between 18 and 60 years of age, inclusive at the time of signing the informed consent document.
  • Diagnosis of cyclic vomiting syndrome (CVS) using the Rome IV diagnostic criteria.
  • Otherwise healthy, as determined by the responsible physician, based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs) and laboratory tests assessed at the screening visit
  • Negative urine tests for selected drugs of abuse and alcohol breath test at Screening.

Exclusion Criteria:

  • Any significant medical or psychiatric condition that could, in the Investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol.
  • Any condition, including the presence of laboratory abnormalities or pulmonary condition, which according to the Investigator places the subject at unacceptable risk if he/she were to participate in the study.
  • A diagnosis of any gastrointestinal disorder other than CVS that in the judgement of the Investigator could compromise the subject's safety or interfere with the interpretation of safety or efficacy data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04645953


Contacts
Layout table for location contacts
Contact: Mike Nelson 650-730-5508 mnelson@alexza.com

Locations
Show Show 18 study locations
Sponsors and Collaborators
Alexza Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Larry Carter, PhD Alexza Pharmaceuticals, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: Alexza Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04645953    
Other Study ID Numbers: AMDC 010-201
First Posted: November 27, 2020    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Alexza Pharmaceuticals, Inc.:
Cyclic Vomiting Syndrome
CVS
Vomiting
Retching
Abdominal migraine
Nausea
Stomach pain
Unexplained vomiting
Functional GI Disorder
CVSHOPE.com
Throwing up
Puking
Dry heaving
Food poisoning
Episodes
Repeated food poisoning
Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Vomiting
Disease
Pathologic Processes
Signs and Symptoms, Digestive